Additional studies nevertheless have to prove how useful pERK is as a marker for tamoxifen resistance in pre-menopausal breast cancer as well as identifying alternative and potentially more stable markers for activation of ERK that can be useful in clinical routine analyses. The gene discussed is MAPK1; the disease is breast cancer.